Antibe Therapeutics Inc.
ATBPF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $9,713 | $9,666 |
| % Growth | – | -100% | 0.5% | – |
| Cost of Goods Sold | $0 | $99 | $6,163 | $5,970 |
| Gross Profit | $0 | -$99 | $3,550 | $3,696 |
| % Margin | – | – | 36.5% | 38.2% |
| R&D Expenses | $12,323 | $14,358 | $15,732 | $9,094 |
| G&A Expenses | $8,907 | $10,963 | $9,988 | $8,611 |
| SG&A Expenses | $9,238 | $11,171 | $10,103 | $12,383 |
| Sales & Mktg Exp. | $331 | $208 | $115 | $3,772 |
| Other Operating Expenses | $0 | $0 | $0 | $1,854 |
| Operating Expenses | $20,546 | $25,529 | $23,530 | $22,314 |
| Operating Income | -$20,546 | -$25,529 | -$23,531 | -$18,618 |
| % Margin | – | – | -242.3% | -192.6% |
| Other Income/Exp. Net | $1,255 | $279 | -$322 | -$440 |
| Pre-Tax Income | -$19,291 | -$25,250 | -$24,734 | -$19,058 |
| Tax Expense | $184 | -$182 | $1,803 | -$7 |
| Net Income | -$19,475 | -$25,060 | -$26,301 | -$19,343 |
| % Margin | – | – | -270.8% | -200.1% |
| EPS | -0.37 | -0.49 | -0.7 | -0.71 |
| % Growth | 24.5% | 30% | 1.4% | – |
| EPS Diluted | -0.37 | -0.49 | -0.7 | -0.71 |
| Weighted Avg Shares Out | 52,286 | 50,774 | 37,252 | 27,267 |
| Weighted Avg Shares Out Dil | 52,286 | 50,774 | 37,252 | 27,267 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,353 | $282 | $37 | $99 |
| Interest Expense | $8 | $8 | $6 | $500 |
| Depreciation & Amortization | $99 | $99 | $478 | $571 |
| EBITDA | -$19,193 | -$25,148 | -$23,007 | -$17,979 |
| % Margin | – | – | -236.9% | -186% |